Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 42%
Buy 47%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly has demonstrated strong revenue growth across multiple key segments, with cardiovascular revenues increasing by 16.1% year-over-year and neuromodulation revenues rising by 10% year-over-year in the fourth quarter. Notably, the company’s focus on innovative products such as Mounjaro and Verzenio has positioned it well within the rapidly evolving healthcare landscape, particularly in the cardiometabolic and oncology markets. Moreover, sustained growth projections for the electrophysiology market, estimated at around 15% annually, support Eli Lilly's potential for exceeding overall market performance in the coming years.

Bears say

Eli Lilly faced an 18% decline in its stock price following the release of disappointing Q4 results and a guidance for 2026 that fell short of consensus expectations, particularly within the electrophysiology (EP) segment. Factors contributing to a negative outlook include potential pricing and rebate pressures, slower-than-expected adoption of new products and M&A activities, and concerns regarding the efficacy of its key medications like tirzepatide in specific patient populations. Additionally, higher debt levels resulting from M&A could lead to negative financial leverage, creating further uncertainty around the company's growth trajectory and operational leverage ambitions.

Eli Lilly (LLY) has been analyzed by 19 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 47% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 19 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Apr 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,195.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,195.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.